Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81


The True Story and Advantages of RNA Phage Capsids as Nanotools.

Pumpens P, Renhofa R, Dishlers A, Kozlovska T, Ose V, Pushko P, Tars K, Grens E, Bachmann MF.

Intervirology. 2016;59(2):74-110. doi: 10.1159/000449503. Epub 2016 Nov 10. Review.


[The true story and advantages of the famous Hepatitis B virus core particles: Outlook 2016].

Pumpens P, Grens E.

Mol Biol (Mosk). 2016 Jul-Aug;50(4):558-576. Russian.


The Hepatitis B Virus Core Variants that Expose Foreign C-Terminal Insertions on the Outer Surface of Virus-Like Particles.

Dishlers A, Skrastina D, Renhofa R, Petrovskis I, Ose V, Lieknina I, Jansons J, Pumpens P, Sominskaya I.

Mol Biotechnol. 2015 Dec;57(11-12):1038-49. doi: 10.1007/s12033-015-9895-9.


Preparation by alkaline treatment and detailed characterisation of empty hepatitis B virus core particles for vaccine and gene therapy applications.

Strods A, Ose V, Bogans J, Cielens I, Kalnins G, Radovica I, Kazaks A, Pumpens P, Renhofa R.

Sci Rep. 2015 Jun 26;5:11639. doi: 10.1038/srep11639.


Silica nanoparticles as the adjuvant for the immunisation of mice using hepatitis B core virus-like particles.

Skrastina D, Petrovskis I, Lieknina I, Bogans J, Renhofa R, Ose V, Dishlers A, Dekhtyar Y, Pumpens P.

PLoS One. 2014 Dec 1;9(12):e114006. doi: 10.1371/journal.pone.0114006. eCollection 2014.


Hepatitis C virus hypervariable region 1 variants presented on hepatitis B virus capsid-like particles induce cross-neutralizing antibodies.

Lange M, Fiedler M, Bankwitz D, Osburn W, Viazov S, Brovko O, Zekri AR, Khudyakov Y, Nassal M, Pumpens P, Pietschmann T, Timm J, Roggendorf M, Walker A.

PLoS One. 2014 Jul 11;9(7):e102235. doi: 10.1371/journal.pone.0102235. eCollection 2014.


Mosaic RNA phage VLPs carrying domain III of the West Nile virus E protein.

Cielens I, Jackevica L, Strods A, Kazaks A, Ose V, Bogans J, Pumpens P, Renhofa R.

Mol Biotechnol. 2014 May;56(5):459-69. doi: 10.1007/s12033-014-9743-3.


A VLP library of C-terminally truncated Hepatitis B core proteins: correlation of RNA encapsidation with a Th1/Th2 switch in the immune responses of mice.

Sominskaya I, Skrastina D, Petrovskis I, Dishlers A, Berza I, Mihailova M, Jansons J, Akopjana I, Stahovska I, Dreilina D, Ose V, Pumpens P.

PLoS One. 2013 Sep 23;8(9):e75938. doi: 10.1371/journal.pone.0075938. eCollection 2013.


Chimeric derivatives of hepatitis B virus core particles carrying major epitopes of the rubella virus E1 glycoprotein.

Skrastina D, Petrovskis I, Petraityte R, Sominskaya I, Ose V, Lieknina I, Bogans J, Sasnauskas K, Pumpens P.

Clin Vaccine Immunol. 2013 Nov;20(11):1719-28. doi: 10.1128/CVI.00533-13. Epub 2013 Sep 4.


Development of virus-like particle technology from small highly symmetric to large complex virus-like particle structures.

Pushko P, Pumpens P, Grens E.

Intervirology. 2013;56(3):141-65. doi: 10.1159/000346773. Epub 2013 Apr 16. Review.


Posttranslational modifications and secretion efficiency of immunogenic hepatitis B virus L protein deletion variants.

Niedre-Otomere B, Bogdanova A, Bruvere R, Ose V, Gerlich WH, Pumpens P, Glebe D, Kozlovska T.

Virol J. 2013 Feb 25;10:63. doi: 10.1186/1743-422X-10-63.


Recombinant Semliki Forest virus vectors encoding hepatitis B virus small surface and pre-S1 antigens induce broadly reactive neutralizing antibodies.

Niedre-Otomere B, Bogdanova A, Skrastina D, Zajakina A, Bruvere R, Ose V, Gerlich WH, Garoff H, Pumpens P, Glebe D, Kozlovska T.

J Viral Hepat. 2012 Sep;19(9):664-73. doi: 10.1111/j.1365-2893.2012.01594.x. Epub 2012 May 17.


Structures of hepatitis B virus cores presenting a model epitope and their complexes with antibodies.

Roseman AM, Borschukova O, Berriman JA, Wynne SA, Pumpens P, Crowther RA.

J Mol Biol. 2012 Oct 12;423(1):63-78. doi: 10.1016/j.jmb.2012.06.032. Epub 2012 Jun 28.


Fibronectin-binding nanoparticles for intracellular targeting addressed by B. burgdorferi BBK32 protein fragments.

Ranka R, Petrovskis I, Sominskaya I, Bogans J, Bruvere R, Akopjana I, Ose V, Timofejeva I, Brangulis K, Pumpens P, Baumanis V.

Nanomedicine. 2013 Jan;9(1):65-73. doi: 10.1016/j.nano.2012.05.003. Epub 2012 May 23.


Universal vaccine against influenza virus: linking TLR signaling to anti-viral protection.

Schmitz N, Beerli RR, Bauer M, Jegerlehner A, Dietmeier K, Maudrich M, Pumpens P, Saudan P, Bachmann MF.

Eur J Immunol. 2012 Apr;42(4):863-9. doi: 10.1002/eji.201041225.


T helper and B cell escape mutations within the HBc gene in patients with asymptomatic HBV infection: a study from the South-Eastern region of Iran.

Assar S, Arababadi MK, Mohit M, Ahmadabadi BN, Pumpens P, Khorramdelazad H, Hajghani M, Assar S, Araste M, Nekhei Z, Sendi H, Kennedy D.

Clin Lab. 2012;58(1-2):53-60.


Potato virus Y-like particles as a new carrier for the presentation of foreign protein stretches.

Kalnciema I, Skrastina D, Ose V, Pumpens P, Zeltins A.

Mol Biotechnol. 2012 Oct;52(2):129-39. doi: 10.1007/s12033-011-9480-9.


N-terminal myristoylation-dependent masking of neutralizing epitopes in the preS1 attachment site of hepatitis B virus.

Bremer CM, Sominskaya I, Skrastina D, Pumpens P, El Wahed AA, Beutling U, Frank R, Fritz HJ, Hunsmann G, Gerlich WH, Glebe D.

J Hepatol. 2011 Jul;55(1):29-37. doi: 10.1016/j.jhep.2010.10.019. Epub 2010 Nov 28.


Highly efficient production of phosphorylated hepatitis B core particles in yeast Pichia pastoris.

Freivalds J, Dislers A, Ose V, Pumpens P, Tars K, Kazaks A.

Protein Expr Purif. 2011 Feb;75(2):218-24. doi: 10.1016/j.pep.2010.09.010. Epub 2010 Sep 18.


Identification of the rheumatoid arthritis shared epitope binding site on calreticulin.

Ling S, Cheng A, Pumpens P, Michalak M, Holoshitz J.

PLoS One. 2010 Jul 22;5(7):e11703. doi: 10.1371/journal.pone.0011703.


A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice.

Spohn G, Jennings GT, Martina BE, Keller I, Beck M, Pumpens P, Osterhaus AD, Bachmann MF.

Virol J. 2010 Jul 6;7:146. doi: 10.1186/1743-422X-7-146.


Immune dysregulation by the rheumatoid arthritis shared epitope.

De Almeida DE, Ling S, Pi X, Hartmann-Scruggs AM, Pumpens P, Holoshitz J.

J Immunol. 2010 Aug 1;185(3):1927-34. doi: 10.4049/jimmunol.0904002. Epub 2010 Jun 30.


Construction and immunological evaluation of multivalent hepatitis B virus (HBV) core virus-like particles carrying HBV and HCV epitopes.

Sominskaya I, Skrastina D, Dislers A, Vasiljev D, Mihailova M, Ose V, Dreilina D, Pumpens P.

Clin Vaccine Immunol. 2010 Jun;17(6):1027-33. doi: 10.1128/CVI.00468-09. Epub 2010 Apr 21.


Versatile virus-like particle carrier for epitope based vaccines.

Tissot AC, Renhofa R, Schmitz N, Cielens I, Meijerink E, Ose V, Jennings GT, Saudan P, Pumpens P, Bachmann MF.

PLoS One. 2010 Mar 23;5(3):e9809. doi: 10.1371/journal.pone.0009809.


CTL escape mutations of core protein are more frequent in strains of HBeAg negative patients with low levels of HBV DNA.

Sendi H, Mehrab-Mohseni M, Shahraz S, Norder H, Alavian SM, Noorinayer B, Zali MR, Pumpens P, Bonkovsky HL, Magnius LO.

J Clin Virol. 2009 Nov;46(3):259-64. doi: 10.1016/j.jcv.2009.08.002. Epub 2009 Sep 12.


Nuclear entry of hepatitis B virus capsids involves disintegration to protein dimers followed by nuclear reassociation to capsids.

Rabe B, Delaleau M, Bischof A, Foss M, Sominskaya I, Pumpens P, Cazenave C, Castroviejo M, Kann M.

PLoS Pathog. 2009 Aug;5(8):e1000563. doi: 10.1371/journal.ppat.1000563. Epub 2009 Aug 28.


Alveolar macrophages and lung dendritic cells sense RNA and drive mucosal IgA responses.

Bessa J, Jegerlehner A, Hinton HJ, Pumpens P, Saudan P, Schneider P, Bachmann MF.

J Immunol. 2009 Sep 15;183(6):3788-99. doi: 10.4049/jimmunol.0804004. Epub 2009 Aug 26.


Enhancement of the expression of HCV core gene does not enhance core-specific immune response in DNA immunization: advantages of the heterologous DNA prime, protein boost immunization regimen.

Alekseeva E, Sominskaya I, Skrastina D, Egorova I, Starodubova E, Kushners E, Mihailova M, Petrakova N, Bruvere R, Kozlovskaya T, Isaguliants M, Pumpens P.

Genet Vaccines Ther. 2009 Jun 8;7:7. doi: 10.1186/1479-0556-7-7.


Melanoma vaccine candidates from chimeric hepatitis B core virus-like particles carrying a tumor-associated MAGE-3 epitope.

Kazaks A, Balmaks R, Voronkova T, Ose V, Pumpens P.

Biotechnol J. 2008 Nov;3(11):1429-36. doi: 10.1002/biot.200800160.


High immunogenicity of a hydrophilic component of the hepatitis B virus preS1 sequence exposed on the surface of three virus-like particle carriers.

Skrastina D, Bulavaite A, Sominskaya I, Kovalevska L, Ose V, Priede D, Pumpens P, Sasnauskas K.

Vaccine. 2008 Apr 7;26(16):1972-81. doi: 10.1016/j.vaccine.2008.02.030. Epub 2008 Feb 26.


Monoclonal antibodies providing topological information on the duck hepatitis B virus core protein and avihepadnaviral nucleocapsid structure.

Vorreiter J, Leifer I, Rösler C, Jackevica L, Pumpens P, Nassal M.

J Virol. 2007 Dec;81(23):13230-4. Epub 2007 Sep 19.


Proteasomal degradation of core protein variants from chronic hepatitis B patients.

Braun S, Zajakina A, Aleksejeva J, Sharipo A, Bruvere R, Ose V, Pumpens P, Garoff H, Meisel H, Kozlovska T.

J Med Virol. 2007 Sep;79(9):1312-21.


Activation of nitric oxide signaling by the rheumatoid arthritis shared epitope.

Ling S, Lai A, Borschukova O, Pumpens P, Holoshitz J.

Arthritis Rheum. 2006 Nov;54(11):3423-32.


Hamster polyomavirus-derived virus-like particles are able to transfer in vitro encapsidated plasmid DNA to mammalian cells.

Voronkova T, Kazaks A, Ose V, Ozel M, Scherneck S, Pumpens P, Ulrich R.

Virus Genes. 2007 Jun;34(3):303-14. Epub 2006 Aug 22.


Preparation of hepatitis C virus structural and non-structural protein fragments and studies of their immunogenicity.

Mihailova M, Fiedler M, Boos M, Petrovskis I, Sominskaya I, Roggendorf M, Viazov S, Pumpens P.

Protein Expr Purif. 2006 Nov;50(1):43-8. Epub 2006 Jun 27.


Recombinant virus-like particles as a carrier of B- and T-cell epitopes of hepatitis C virus (HCV).

Mihailova M, Boos M, Petrovskis I, Ose V, Skrastina D, Fiedler M, Sominskaya I, Ross S, Pumpens P, Roggendorf M, Viazov S.

Vaccine. 2006 May 15;24(20):4369-77. Epub 2006 Mar 15.


Signal sequences modulate the immunogenic performance of human hepatitis C virus E2 gene.

Sominskaya I, Alekseeva E, Skrastina D, Mokhonov V, Starodubova E, Jansons J, Levi M, Prilipov A, Kozlovska T, Smirnov V, Pumpens P, Isaguliants MG.

Mol Immunol. 2006 May;43(12):1941-52. Epub 2006 Jan 25.


Assembly of bacteriophage Qbeta virus-like particles in yeast Saccharomyces cerevisiae and Pichia pastoris.

Freivalds J, Dislers A, Ose V, Skrastina D, Cielens I, Pumpens P, Sasnauskas K, Kazaks A.

J Biotechnol. 2006 May 29;123(3):297-303. Epub 2006 Jan 6.


A hantavirus nucleocapsid protein segment exposed on hepatitis B virus core particles is highly immunogenic in mice when applied without adjuvants or in the presence of pre-existing anti-core antibodies.

Geldmacher A, Skrastina D, Borisova G, Petrovskis I, Krüger DH, Pumpens P, Ulrich R.

Vaccine. 2005 Jun 10;23(30):3973-83. Epub 2005 Mar 16.


Hepatitis B and C virus variants in long-term immunosuppressed renal transplant patients in Latvia.

Sominskaya I, Mihailova M, Jansons J, Emelyanova V, Folkmane I, Smagris E, Dumpis U, Rozentals R, Pumpens P.

Intervirology. 2005;48(2-3):192-200.


Efficient homologous prime-boost strategies for T cell vaccination based on virus-like particles.

Schwarz K, Meijerink E, Speiser DE, Tissot AC, Cielens I, Renhof R, Dishlers A, Pumpens P, Bachmann MF.

Eur J Immunol. 2005 Mar;35(3):816-21.


Translation of hepatitis B virus (HBV) surface proteins from the HBV pregenome and precore RNAs in Semliki Forest virus-driven expression.

Zajakina A, Kozlovska T, Bruvere R, Aleksejeva J, Pumpens P, Garoff H.

J Gen Virol. 2004 Nov;85(Pt 11):3343-51.


Mosaic hepatitis B virus core particles presenting the complete preS sequence of the viral envelope on their surface.

Kazaks A, Borisova G, Cvetkova S, Kovalevska L, Ose V, Sominskaya I, Pumpens P, Skrastina D, Dislers A.

J Gen Virol. 2004 Sep;85(Pt 9):2665-70.


An amino-terminal segment of hantavirus nucleocapsid protein presented on hepatitis B virus core particles induces a strong and highly cross-reactive antibody response in mice.

Geldmacher A, Skrastina D, Petrovskis I, Borisova G, Berriman JA, Roseman AM, Crowther RA, Fischer J, Musema S, Gelderblom HR, Lundkvist A, Renhofa R, Ose V, Krüger DH, Pumpens P, Ulrich R.

Virology. 2004 May 20;323(1):108-19.


Mosaic particles formed by wild-type hepatitis B virus core protein and its deletion variants consist of both homo- and heterodimers.

Kazaks A, Dishlers A, Pumpens P, Ulrich R, Krüger DH, Meisel H.

FEBS Lett. 2003 Aug 14;549(1-3):157-62.


Stop codon insertion restores the particle formation ability of hepatitis B virus core-hantavirus nucleocapsid protein fusions.

Kazaks A, Lachmann S, Koletzki D, Petrovskis I, Dislers A, Ose V, Skrastina D, Gelderblom HR, Lundkvist A, Meisel H, Borisova G, Krüger DH, Pumpens P, Ulrich R.

Intervirology. 2002;45(4-6):340-9.


Molecular epidemiology and immunology of hepatitis B virus infection - an update.

Pumpens P, Grens E, Nassal M.

Intervirology. 2002;45(4-6):218-32. Review.


Regulation of IgG antibody responses by epitope density and CD21-mediated costimulation.

Jegerlehner A, Storni T, Lipowsky G, Schmid M, Pumpens P, Bachmann MF.

Eur J Immunol. 2002 Nov;32(11):3305-14.


Priming of cytotoxic T cell responses to exogenous hepatitis B virus core antigen is B cell dependent.

Lazdina U, Alheim M, Nyström J, Hultgren C, Borisova G, Sominskaya I, Pumpens P, Peterson DL, Milich DR, Sällberg M.

J Gen Virol. 2003 Jan;84(Pt 1):139-46.


Supplemental Content

Loading ...
Support Center